Liquidia Corporation - Common Stock (LQDA)
26.68
+0.77 (2.97%)
NASDAQ · Last Trade: Oct 7th, 5:23 PM EDT
Detailed Quote
| Previous Close | 25.91 |
|---|---|
| Open | 25.55 |
| Bid | 26.44 |
| Ask | 26.50 |
| Day's Range | 24.59 - 27.33 |
| 52 Week Range | 21.94 - 93.61 |
| Volume | 6,964,218 |
| Market Cap | 2.29B |
| PE Ratio (TTM) | -32.94 |
| EPS (TTM) | -0.8 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 4,113,172 |
Chart
About Liquidia Corporation - Common Stock (LQDA)
Liquidia Corp is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with rare and serious diseases. Utilizing its proprietary PRINT technology, Liquidia designs and manufactures novel drug formulations that enhance the delivery and effectiveness of established medications. The company is dedicated to addressing unmet medical needs by advancing its product pipeline, which targets various conditions, including pulmonary and cardiovascular diseases. Through its commitment to research and development, Liquidia aims to improve the quality of life for patients through more effective therapeutic options. Read More
News & Press Releases
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Liquidia (LQDA) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · October 7, 2026
NEW YORK CITY, NY / ACCESS Newswire / October 7, 2026 / Liquidia Corporation (NASDAQ:LQDA) shares fell roughly 57% after a court ruled that Yutrepia infringes two valid claims of United Therapeutics' '327 patent. If you held LQDA when the ruling hit and lost money, you may have legal rights. Shareholders who suffered losses are encouraged to submit their loss information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
By Levi & Korsinsky, LLP · Via ACCESS Newswire · October 7, 2026
Top movers analysis one hour before the close of the markets on 2026-09-30: top gainers and losers in today's session.chartmill.com
Via Chartmill · September 30, 2026
MORRISVILLE, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding the litigation filed by United Therapeutics Corporation (UTHR) in the U.S. District Court for the District of Delaware (the Court) under the Hatch-Waxman Act concerning U.S. Patent No. 11,826,327 (‘327 patent) and the Company’s lead product, YUTREPIA® (treprostinil) inhalation powder.
By Liquidia Technologies, Inc. · Via GlobeNewswire · September 30, 2026
Liquidia (NASDAQ:LQDA) High Growth Momentum Meets a Pre-Breakout Setupchartmill.com
Via Chartmill · September 30, 2026
Liquidia (NASDAQ:LQDA): Strong Growth Paired With Technical Setup Qualitychartmill.com
Via Chartmill · September 19, 2026
LIQUIDIA CORP (NASDAQ:LQDA) Fits the Affordable Growth Screenchartmill.com
Via Chartmill · September 9, 2026
Let's take a look at the stocks that are in motion in today's session.chartmill.com
Via Chartmill · September 30, 2026
MORRISVILLE, N.C., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP). The potential use of YUTREPIA in SSc-RP is currently under clinical development, and its safety and efficacy for this indication have not been evaluated by any regulatory authority.
By Liquidia Technologies, Inc. · Via GlobeNewswire · September 3, 2026
MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.
By Liquidia Technologies, Inc. · Via GlobeNewswire · September 2, 2026
MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company’s business in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m. ET.
By Liquidia Technologies, Inc. · Via GlobeNewswire · September 1, 2026
Liquidia Corp (NASDAQ:LQDA) Shows High Growth Momentum With a Breakout Setupchartmill.com
Via Chartmill · August 12, 2026
LIQUIDIA CORP (NASDAQ:LQDA): A High Growth Stock with a Strong Technical Setupchartmill.com
Via Chartmill · July 28, 2026
Liquidia Corp (NASDAQ:LQDA): An Affordable Growth Stock With Explosive Revenue Momentum and Reasonable Forward Valuationchartmill.com
Via Chartmill · July 20, 2026
Liquidia Corp. (NASDAQ:LQDA) Flashes Perfect 10/10 Technical Score on Minervini Trend Template and High Growth Momentumchartmill.com
Via Chartmill · June 18, 2026
YUTREPIA sales hit $170.4 million with 5,000+ patients started on therapy.
Via The Motley Fool · August 19, 2026
It needed to post a blowout quarter instead of the good one it delivered.
Via The Motley Fool · August 14, 2026
Liquidia (NASDAQ:LQDA) reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline.
Chief Executive Officer Roger Jeffs said the company had received approximately 5,900 uniq
Via MarketBeat · August 12, 2026
Liquidia Corp (NASDAQ:LQDA): Affordable Growth Play With Explosive Revenuechartmill.com
Via Chartmill · June 10, 2026
MORRISVILLE, N.C., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the second quarter ended June 30, 2026. The company will also host a webcast at 8:30 a.m. ET on August 12, 2026, to discuss its financial results and provide a corporate update.
By Liquidia Technologies, Inc. · Via GlobeNewswire · August 12, 2026
MORRISVILLE, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will report its second quarter 2026 financial results on Wednesday, August 12, 2026. The company will host a live webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update.
By Liquidia Technologies, Inc. · Via GlobeNewswire · July 29, 2026
Liquidia (NASDAQ:LQDA) released first-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below. Benzinga APIs provide real-time access to earnings call transcripts and
Via Benzinga · June 26, 2026
MORRISVILLE, N.C., June 11, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that the company will present four posters at the PHA 2026 International PH Conference and Scientific Sessions taking place June 11-14 in Dallas.
By Liquidia Technologies, Inc. · Via GlobeNewswire · June 11, 2026
MORRISVILLE, N.C., June 08, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, announced today that it will be added to the S&P SmallCap 600® Index, effective prior to the opening of trading on June 22, 2026.
By Liquidia Technologies, Inc. · Via GlobeNewswire · June 8, 2026
MORRISVILLE, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA) today announced that Dr. Roger Jeffs, Chief Executive Officer, and Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will provide an update on the company’s business in a fireside chat at the Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026, at 12:45 p.m. ET.
By Liquidia Technologies, Inc. · Via GlobeNewswire · May 27, 2026